Chinese upgrades to Cambodia's Ream Naval Base ‘aimed at de-risking supply chains'
Cambodia is part of Beijing's bigger plan to break maritime chokepoints and de-risk supply chains, according to a Hong Kong-based analyst.
Advertisement
Chinese and Cambodian officials, including Cambodian Prime Minister Hun Manet and members of the People's Liberation Army (PLA), attended a ceremony at the Ream Naval Base to launch the new facilities on Saturday.
The upgrades include a joint logistics and training centre and a 650-metre (2,130-foot) pier that can handle big warships such as aircraft carriers – vessels that Cambodia's navy does not have.
The Chinese defence ministry said the facility was designed to 'strengthen practical military cooperation' – supporting regional counterterrorism, humanitarian assistance and disaster relief.
The ministry added that it 'does not target any third party' – an apparent reference to US concerns about potential exclusive PLA access to the site.
02:04
China helps upgrade Cambodian naval base, as nations dismiss Western fears about Beijing's plans
China helps upgrade Cambodian naval base, as nations dismiss Western fears about Beijing's plans
Brian Wong, a fellow at the Centre on Contemporary China and the World at the University of Hong Kong, said the facility reflected Beijing's strategic efforts to diversify regional maritime access as part of its broader Belt and Road Initiative.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
an hour ago
- South China Morning Post
Hong Kong stocks snap 4-day decline as US jobs data fuels Fed rate-cut bets
Hong Kong stocks started the week's trading on a solid note on Monday, as the benchmark gauge ended a four-day streak of declines on rising hopes of a US interest-rate cut after data showed a worsening US labour market. The Hang Seng Index rose 0.3 per cent to 24,586.60 as of 10.14am local time. The Hang Seng Tech Index gained 0.7 per cent. On the mainland, the CSI 300 Index slipped 0.1 per cent, and the Shanghai Composite Index added 0.1 per cent. China Resources Land advanced 2.5 per cent to HK$29.32 and Zijin Mining rallied 2.5 per cent to HK$21.68 on a flight to gold in haven trade. Limiting the gains, electric-vehicle maker BYD tumbled 3.4 per cent to HK$112.80 and China Life Insurance lost 2.3 per cent to HK$21.64. Alibaba Group Holding fell 1.2 per cent to HK$115.50. Some analysts are now anticipating the Federal Reserve may cut rates by half a point in September, double the regular reduction amount. The US central bank stood pat on the borrowing cost last week for a fifth meeting in a row. US stocks tumbled on Friday after official data showed that job creation fell far short of the consensus estimates in July, while unemployment increased. The Bureau of Labor Statistics also revised downward the data on the jobs market for the previous two months, prompting President Donald Trump to fire Erika McEntarfer, the commissioner of the agency. Investors are struggling to search for new catalysts that could underpin the rally that drove the Hang Seng Index to its highest in three and a half years last month. A Politburo meeting that concluded last week failed to impress the market, with no hints of additional stimulus measures on the horizon.
South China Morning Post
2 hours ago
- South China Morning Post
Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups
Innovent likely to post a first-half net profit of US$36.4 illion, and BeOne's first-half net rofit is expected to come in at US$42 million A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. 'Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,' said Tony Ren, head of Asia healthcare research at Macquarie Capital, in a report on July 16. '[Some will] likely turn profitable soon and no longer rely on investors for funding.' Suzhou-based Innovent Biologics, the first Chinese company to be approved to sell a drug for weight loss and diabetes, is expected to swing to a first-half net profit of 260 million yuan (US$36.4 million) from a year-earlier loss of 392.6 million yuan, according to an estimate from Zhang Jialin, Nomura's head of China healthcare research. According to a consensus estimate from Bloomberg, the company was expected to post a net profit of 472 million yuan for 2025, its first full-year profit since going public. Innovent, founded in 2011, was one of the first batch of firms to go public in 2018 under a Hong Kong listing regime that allowed drug and medical device developers with no profit or revenue to sell shares. Innovent Biologics is expected to post a first-half net profit of 260 million yuan compared with a loss of 392.6 million yuan a year earlier. Photo: Handout In the second half, Zhang estimated that Innovent would book 1 billion yuan in sales from mazdutide, a glucagon-like peptide-1 (GLP-1) weight loss drug launched in July. That would amount to a sixth of the company's total expected revenue for this year, making it a key contributor to the improved bottom line. Novo Nordisk's semaglutide, the first GLP-1 drug launched in China last year for weight loss, generated revenue of 770 million yuan in the first quarter. A researcher using a micropipette pipette in a lab. Photo: Shutterstock BeOne, a developer of oncology drugs that was established in 2010, was expected by analysts to post a net profit of US$42 million for the first half and a full-year profit of US$109.5 million. The company will announce its first-half results on August 6. Newsletter Every Saturday SCMP Global Impact By submitting, you consent to receiving marketing emails from SCMP. If you don't want these, tick here {{message}} Thanks for signing up for our newsletter! Please check your email to confirm your subscription. Follow us on Facebook to get our latest news. The company's profit growth was driven primarily by sales of its blood cancer drug zanubrutinib in the US and Europe, Zhang said. Innovent and BeOne, along with other Chinese biotech firms like Akeso, have booked billions of yuan in upfront revenue over the past few years from licensing drug candidates to multinational partners for overseas development. But despite an increase in deals in recent years, milestone payments in the drug development process were hard to predict because collaborations were often cut short due to shifting competitive considerations and regulatory hurdles, Macquarie's Ren said. For example, the US Food and Drug Administration (FDA) in March 2022 rejected an application from Eli Lilly to sell Innovent's lead oncology drug, sintilimab, to treat the most common type of lung cancer in the US, even though it was approved in China a year earlier. While the FDA recommended that an additional multi-regional clinical study be conducted, the drug has still not been approved in the US. In mid-2019, Celgene returned to BeOne the exclusive right to develop and commercialise the Chinese firm's immunotherapy drug candidate, tislelizumab, ahead of Celgene's impending acquisition by Bristol-Myers Squibb. The American drug firm already had an approved treatment in the same category. Celgene terminated the deal by paying BeOne US$150 million. In 2021, BeOne re-licensed the rights for the same drug to Switzerland's Novartis, which in 2023 returned them, citing a changing market landscape. BeOne subsequently took over the drug's development and won approvals to launch it in the European Union and the US. 'Most licensing deals, including ones from China, are small [in actual payments] and hardly affect the licensers' financial performance over the medium to long term,' Ren said.
South China Morning Post
2 hours ago
- South China Morning Post
Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups
A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. Advertisement 'Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,' said Tony Ren, head of Asia healthcare research at Macquarie Capital, in a report on July 16. '[Some will] likely turn profitable soon and no longer rely on investors for funding.' Suzhou-based Innovent Biologics , the first Chinese company to be approved to sell a drug for weight loss and diabetes, is expected to swing to a first-half net profit of 260 million yuan (US$36.4 million) from a year-earlier loss of 392.6 million yuan, according to an estimate from Zhang Jialin, Nomura's head of China healthcare research. According to a consensus estimate from Bloomberg, the company was expected to post a net profit of 472 million yuan for 2025, its first full-year profit since going public. Innovent, founded in 2011, was one of the first batch of firms to go public in 2018 under a Hong Kong listing regime that allowed drug and medical device developers with no profit or revenue to sell shares. Innovent Biologics is expected to post a first-half net profit of 260 million yuan compared with a loss of 392.6 million yuan a year earlier. Photo: Handout In the second half, Zhang estimated that Innovent would book 1 billion yuan in sales from mazdutide, a glucagon-like peptide-1 (GLP-1) weight loss drug launched in July. Advertisement That would amount to a sixth of the company's total expected revenue for this year, making it a key contributor to the improved bottom line. Novo Nordisk's semaglutide, the first GLP-1 drug launched in China last year for weight loss, generated revenue of 770 million yuan in the first quarter.
